financetom
Business
financetom
/
Business
/
Sweden's EQT bids to buy Australia's AUB Group at a $3.41 billion valuation
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sweden's EQT bids to buy Australia's AUB Group at a $3.41 billion valuation
Oct 27, 2025 4:05 PM

(Reuters) -Australia's AUB Group ( AUBBF ) said on Tuesday it had granted Swedish private equity EQT exclusive access to its books after receiving a takeover offer which values the insurance broking company at A$5.25 billion ($3.41 billion). 

Under the proposal, EQT is offering A$45 per AUB share, which reflects a 25.1% premium to the Australian company's last close. 

The A$45 apiece offer follows a previous approach, where the buyer had bid A$43 per share in cash.

The company said it had entered a confidentiality and exclusivity agreement with EQT and has provided the private equity firm access to its books for a six-week period, which began on October 8.

The news comes as AUB Group's ( AUBBF ) shares have largely stagnated over the past year despite steady institutional interest, underperforming both its rival, Steadfast Group ( SFGLF ), and the broader market.

AUB paused trading on Monday after the stock jumped more than 12%, saying it would respond to media reports and the sharp rise in its share price.

The deal is on the heels of AUB continuing to adjust to changes in its shareholder base, following U.S. private equity firm Odyssey Investment Partners' near A$277 million sell-down last year. 

The company currently counts First Sentier Investors and Capital World Investors as its top two shareholders, according to data compiled by LSEG.

Global firms and private equity investors have been active buyers in Australia, betting on steady premium growth and resilient cash flows even in volatile markets. 

EQT is a name known for acquisitions, having very recently looked at Perpetual's wealth and corporate trust business.   

($1 = 1.5389 Australian dollars)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved